

ALLIA.143A



RECEIVED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant : H. Zaghouani

Appl. No. : 08/779,767

Filed : January 7, 1997

For : COMPOUNDS, CONDITIONS,
AND METHODS FOR THE
ENDOCYTIC
PRESENTATION OF
INNUMOSUPPRESSIVE
FACTORS

Examiner : P. Nolan

) Group Art Unit 1664

)
) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

) October 19, 2000

) (Date)

) Daniel Hart, Reg. No. 40,637

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action mailed April 13, 2000 in the above-identified application, kindly amend the application as follows.

IN THE CLAIMS:

9. (Amended) The composition of Claim 66 wherein the composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist **[derived from proteolipid protein]** is covalently joined to said immunoglobulin or portion thereof.

11. (Amended) The composition of Claim 9 wherein the protein fragment or peptide comprising said T cell receptor antagonist **[derived from proteolipid protein]** is positioned